Inhibition of mTOR by temsirolimus overcomes radio‐resistance in nasopharyngeal carcinoma

ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K/AKT/mTOR Signaling Pathway in Nasopharyngeal Carcinoma

(2020) Qianping Chen et al.   Frontiers in Cell and Developmental Biology

VEGF knockdown enhances radiosensitivity of nasopharyngeal carcinoma by inhibiting autophagy through the activation of mTOR pathway

(2020) Li Chen et al.   Scientific Reports

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy

(2019) Tian Tian et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Development and characterisation of acquired radioresistant breast cancer cell lines

(2019) Mark Gray et al.   Radiation Oncology

Casein kinase 1α-dependent inhibition of Wnt/β-catenin selectively targets nasopharyngeal carcinoma and increases chemosensitivity

(2019) Jiangping Li et al.   ANTI-CANCER DRUGS

Temsirolimus as a dual inhibitor of retinoblastoma and angiogenesis via targeting mTOR signalling

(2019) Zhen Chen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Management of locally recurrent nasopharyngeal carcinoma

(2019) Anne W.M. Lee et al.   CANCER TREATMENT REVIEWS

Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma

(2018) D J Inwards et al.   ANNALS OF ONCOLOGY

Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model

(2018) Hsuen-Wen Chang et al.   Frontiers in Pharmacology

Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer

(2018) Pedro C. Barata et al.   INVESTIGATIONAL NEW DRUGS

Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma

(2017) Hong-Gang Kang et al.   Clinics and Research in Hepatology and Gastroenterology

Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells

(2016) Lin Liu et al.   OncoTargets and Therapy

Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells

(2014) Manabu Kaneko et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Evolution of treatment for nasopharyngeal cancer – Success and setback in the intensity-modulated radiotherapy era

(2014) Anne W.M. Lee et al.   RADIOTHERAPY AND ONCOLOGY

Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1

(2014) Valentina Pirazzoli et al.   Cell Reports

Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance

(2013) Shu-Chen Liu et al.   JOURNAL OF CLINICAL INVESTIGATION

Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma

(2013) MAKIO MORIYA et al.   ONCOLOGY REPORTS

TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma

(2013) R. B. Corcoran et al.   Science Translational Medicine

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110  Inhibitors in PIK3CA-Mutant Breast Cancer

(2013) M. Elkabets et al.   Science Translational Medicine

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

(2009) Brigette B. Y. Ma et al.   INVESTIGATIONAL NEW DRUGS

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

(2008) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

(2008) B. I. Rini   CLINICAL CANCER RESEARCH